Advanced HDX-MS and native MS techniques can be used to improve the identification of potentially successful biologic drugs and take the risk out of CMC and clinical designs.
Jennifer S. Chadwick
Advertisement
Jennifer S. Chadwick, PhD, is director of biologic development at BioAnalytix.
Articles by Jennifer S. Chadwick
Using advanced HDX-MS and native MS techniques can improve the identification of potentially successful biologic drugs and de-risk CMC and clinical designs.
Advertisement
Latest Updated Articles
De-risking Biologics Development Through Advanced Mass Spectrometry ApproachesPublished: August 1st 2019 | Updated:
De-risking Biologics Development Through Advanced Mass Spectrometry ApproachesPublished: September 4th 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Clearing Hurdles in Sustainability, AI, and CDMO Partnerships
2
Drug Digest: Strategic Alliances and Technology Integration in the Evolving Biopharma Landscape
3
Dosage Form Innovations: A CPHI Frankfurt Conversation with Lonza’s Frank Romanski, Part One
4
PharmTech Weekly News Roundup — Week of October 27, 2025
5
